Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,217
  • Shares Outstanding, K 39,495
  • Annual Sales, $ 490 K
  • Annual Income, $ -51,420 K
  • EBIT $ -65 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.31
  • Price/Sales 54.53
  • Price/Cash Flow N/A
  • Price/Book 0.31
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.90
  • Most Recent Earnings $-0.54 on 11/13/25
  • Next Earnings Date 02/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 170.61% (-43.60%)
  • Historical Volatility 470.07%
  • IV Percentile 49%
  • IV Rank 21.79%
  • IV High 518.95% on 11/20/25
  • IV Low 73.56% on 08/01/25
  • Expected Move (DTE 34) 0.8500 (128.05%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 89
  • Volume Avg (30-Day) 2,368
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 48,577
  • Open Int (30-Day) 54,911
  • Expected Range 0.0000 to 1.5138

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.49
  • Low Estimate -0.52
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6311 +5.18%
on 12/31/25
0.9690 -31.50%
on 12/17/25
-3.6962 (-84.78%)
since 12/16/25
3-Month
0.6311 +5.18%
on 12/31/25
5.1400 -87.09%
on 11/24/25
-3.3862 (-83.61%)
since 10/16/25
52-Week
0.6311 +5.18%
on 12/31/25
5.1400 -87.09%
on 11/24/25
-2.2562 (-77.27%)
since 01/16/25

Most Recent Stories

More News
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc.

SAN DIEGO , Jan. 16, 2026 /PRNewswire/ -- Robbins LLP  reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc....

VTGN : 0.6638 (-1.07%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , Jan. 16, 2026 /PRNewswire/ --

VTGN : 0.6638 (-1.07%)
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December...

VTGN : 0.6638 (-1.07%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ:...

VTGN : 0.6638 (-1.07%)
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April...

VTGN : 0.6638 (-1.07%)
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placebo Favorable safety...

VTGN : 0.6638 (-1.07%)
Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...

SENS : 7.76 (+6.74%)
AZN : 94.39 (+0.43%)
VTGN : 0.6638 (-1.07%)
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Research supports the product candidate’s non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkers

VTGN : 0.6638 (-1.07%)
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder is Complete; Topline results expected by calendar year end

VTGN : 0.6638 (-1.07%)
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...

VTGN : 0.6638 (-1.07%)

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 0.7091
2nd Resistance Point 0.6996
1st Resistance Point 0.6817
Last Price 0.6638
1st Support Level 0.6543
2nd Support Level 0.6448
3rd Support Level 0.6269

See More

52-Week High 5.1400
Fibonacci 61.8% 3.4176
Fibonacci 50% 2.8856
Fibonacci 38.2% 2.3535
Last Price 0.6638
52-Week Low 0.6311

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar